Longboard Pharmaceuticals Inc (LBPH) Stock Price & Overview
NASDAQ:LBPH • US54300N1037
Current stock price
The current stock price of LBPH is 59.98 USD. Today LBPH is up by 0.03%. In the past month the price increased by 0.44%. In the past year, price increased by 1399.5%.
LBPH Key Statistics
- Market Cap
- 2.342B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.23
- Dividend Yield
- N/A
LBPH Stock Performance
LBPH Stock Chart
LBPH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LBPH. When comparing the yearly performance of all stocks, LBPH is one of the better performing stocks in the market, outperforming 99.74% of all stocks.
LBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LBPH. While LBPH has a great health rating, there are worries on its profitability.
LBPH Earnings
LBPH Forecast & Estimates
13 analysts have analysed LBPH and the average price target is 65.96 USD. This implies a price increase of 9.97% is expected in the next year compared to the current price of 59.98.
LBPH Groups
Sector & Classification
LBPH Financial Highlights
Over the last trailing twelve months LBPH reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 7.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.7% | ||
| ROE | -27.74% | ||
| Debt/Equity | 0 |
LBPH Ownership
LBPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.94 | 865.533B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 572.592B | ||
| MRK | MERCK & CO. INC. | 22.06 | 282.347B | ||
| PFE | PFIZER INC | 9.03 | 155.861B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.08 | 118.339B | ||
| ZTS | ZOETIS INC | 16.34 | 48.963B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.78 | 26.264B | ||
| VTRS | VIATRIS INC | 5.26 | 15.544B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.8 | 12.489B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.127B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.974B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.21B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.12 | 4.197B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LBPH
Company Profile
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Company Info
IPO: 2021-03-12
Longboard Pharmaceuticals Inc
4275 Executive Square, Suite 950
La Jolla CALIFORNIA 92121 US
CEO: Kevin R. Lind
Employees: 50
Phone: 16195929775
Longboard Pharmaceuticals Inc / LBPH FAQ
What does LBPH do?
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
What is the current price of LBPH stock?
The current stock price of LBPH is 59.98 USD. The price increased by 0.03% in the last trading session.
Does Longboard Pharmaceuticals Inc pay dividends?
LBPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of LBPH stock?
LBPH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is LBPH stock listed?
LBPH stock is listed on the Nasdaq exchange.
What is the employee count for LBPH stock?
Longboard Pharmaceuticals Inc (LBPH) currently has 50 employees.